School of Medicine
Showing 1-50 of 77 Results
-
Michael S Binkley, MD, MS
Assistant Professor of Radiation Oncology (Radiation Therapy)
BioDr. Binkley is a radiation oncologist specializing in lymphoma treatment and an assistant professor in the Stanford University School of Medicine Department of Radiation Oncology.
His clinical expertise includes stereotactic ablative radiotherapy (SABR), total lymphoid and total body irradiation, and intensity modulated radiation therapy (IMRT).
For each patient, Dr. Binkley develops a personalized, comprehensive, and compassionate care plan. His goals are to improve both health and quality of life.
Dr. Binkley has conducted extensive research to advance cancer treatment. In his post-doctoral fellowship at Stanford, he studied the use of genomic signatures to predict response to radiotherapy. His current clinical and laboratory research seek to identify prognostic and predictive clinical, radiographic, and genomic factors to inform individualized treatment strategies.
He has co-authored articles on his research discoveries published in Cancer Discovery, Blood, the International Journal of Radiation Oncology*Biology*Physics, and elsewhere. Topics have included innovations in the treatment of lymphoma and lung cancer.
He also has made invited presentations to colleagues at national and international conferences. He has presented the latest findings on radiation therapy for lung cancer and lymphoma at meetings of the American Society of Clinical Oncology (ASCO), American Society for Radiation Oncology (ASTRO), and International Conference on Malignant Lymphoma (ICML).
Honors for Dr. Binkley include the Malcolm A. Bagshaw Award for leadership and outstanding scientific achievement. This award is named for a pioneer in radiation therapy and former chair of the Departments of Radiology and Radiation Oncology at Stanford University School of Medicine.
Dr. Binkley is a member of the American Society of Clinical Oncology, American Society for Radiation Oncology, and American Association for Cancer Research. He is a founding member of the Global nLPHL One Working (GLOW) Working Group, an international collaboration studying nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in children and adults. -
Mark Buyyounouski, MD, MS, FASTRO
Professor of Radiation Oncology (Radiation Therapy)
Current Research and Scholarly InterestsPatient-centered and artificial intelligence-augmented medical decision making
-
Rishabh Chaudhari, MD
Clinical Assistant Professor, Radiation Oncology - Radiation Therapy
BioDr. Chaudhari is a radiation oncologist with the Stanford Medicine Cancer Center and a clinical assistant professor in the Department of Radiation Oncology at Stanford University School of Medicine.
He specializes in delivering image-guided interventions for all forms of cancer, including lung, breast, prostate, and head and neck. He treats conditions including mesothelioma, seminoma, renal cell carcinoma, and vulvar cancer.
In every case, he develops a comprehensive, compassionate care plan personalized to the unique needs of each patient. His goal is always to deliver innovative, compassionate care of the highest quality to help each patient achieve the best possible outcome.
Dr. Chaudhari conducts research into leading-edge treatments, allowing him to offer the most advanced care options. He has investigated stereotactic body radiation therapy for non-small cell lung cancer and for pancreatic adenocarcinoma. He has also studied the effects of radiotherapy on breast cancer stem cells and extramedullary plasmacytomas. He also is currently studying the use of proton beam therapy on recurrent head and neck cancers.
Dr. Chaudhari has presented his research findings at meetings of the Radiation Research Society, Society for Thermal Medicine, American Society for Radiation Oncology, and World Congress of Brachytherapy. He has published articles on radiotherapy for non-small cell lung cancer in the journal Lung Cancer: Targets and Therapy. He also co-authored the chapter “Renal and Adrenal Vasculature: Anatomy and Imaging” in the textbook Image-Guided Interventions. He is a reviewer for Cancer Medicine.
In previous positions, Dr. Chaudhari served on committees dedicated to care quality assurance and to the monitoring of cancer care protocols. Other areas of interest include radiation oncology department operations and advising radiation oncology residents.
Dr. Chaudhari is a member of the American Society for Radiation Oncology. -
Alexander Chin, MD, MBA
Clinical Assistant Professor, Radiation Oncology - Radiation Therapy
BioAlexander Chin, MD, MBA, is a radiation oncologist with Stanford Medicine Cancer Center and a clinical assistant professor in the Department of Radiation Oncology with the Stanford School of Medicine. He also serves as Director of Market Development for Stanford Health Care, acting as a liaison between faculty leadership and hospital administration, to advance Stanford Medicine’s mission of providing compassionate leading-edge care to the communities that we serve.
Dr. Chin is committed to ensuring the delivery of care of the highest quality and value. He provides clinical expertise in diagnosing and treating the full range of cancers, including those of the lung, breast, and central nervous system. In addition, he serves on national leadership teams formed to advance the practice of cancer care. Dr. Chin is currently a member of the Payment Reform Task Force for the American Society of Clinical Oncology and has previously served on their Clinical Practice Committee and as a health policy fellow. He was one of just two oncologists in the US selected to participate in a year-long program on policy leadership.
He currently serves on the Stanford Cancer Network Quality Committee. This team develops and implements our care delivery standards, strategies, and metrics to ensure consistently excellent cancer care from all Stanford Health Care providers in all locations.
Dr. Chin has conducted extensive research and published his findings in numerous peer-reviewed journals. Topics range from novel oncology payment models to the use of new imaging parameters in lung cancer. His scholarship appears in Cancer, JCO Oncology Practice, Clinical Lung Cancer, International Journal of Radiation Oncology, Biology, Physics, and elsewhere.
He has made presentations on stereotactic body radiotherapy (SBRT) and other treatment advances at meetings of the Radiological Society of North America and American Society for Radiation Oncology. He also has addressed these topics as an invited lecturer in training sessions for oncology residents.
He has won numerous awards, including recognition for his research from the Radiological Society of North America. He also has earned honors from the American Society of Clinical Oncology and from his alma maters: the Perelman School of Medicine at the University of Pennsylvania as well as Wharton and Yale.
Dr. Chin earned a Bachelor of Science degree in molecular biophysics and biochemistry from Yale University. He earned his medical degree from Perelman School of Medicine at the University of Pennsylvania, and his MBA at the Wharton School. He completed his residency in Radiation Oncology at Stanford Health Care.
He is a member of the Radiological Society of North America, American Society for Radiation Oncology, and American Society for Clinical Oncology. -
A. Dimitrios Colevas, MD
Professor of Medicine (Oncology) and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiation Oncology (Radiation Therapy)
Current Research and Scholarly InterestsMulti- modality treatment of Head and Neck Cancer
Phase 1 clinical trials -
Maximilian Diehn, MD, PhD
Jack, Lulu, and Sam Willson Professor and Professor of Radiation Oncology (Radiation Therapy)
Current Research and Scholarly InterestsMy laboratory focuses on two main areas: 1) cancer stem cell biology and 2) novel biomarkers for identifying the presence of malignant cells (diagnostic), predicting outcome (prognostic), and predicting response to therapy (predictive). Areas of study include cancers of the lung, breast, and gastrointestinal system. Clinically I specialize in the treatment of lung cancer and applications of stereotactic ablative radiotherapy and perform both prospective and retrospective clinical studies.
-
Sarah S. Donaldson, MD
Catharine and Howard Avery Professor in the School of Medicine, Emerita
Current Research and Scholarly InterestsCombined Modality Treatment of Cancer
Late Effects of Treatment
Genetic Effects of Cancer
Rhabdomyosarcoma
Hodgkins Disease
Pediatric Radiation Oncolgy
Pediatric Oncolgy
Breast Cancer
Conformal Radiotherapy/IMRT
Radiotherapy for Benign Diseases -
Suparna Dutt
Senior Research Scientist - Basic Life, Radiation Oncology - Radiation Therapy
Current Role at StanfordSr Research Scientist
-
Michael Gensheimer
Clinical Associate Professor, Radiation Oncology - Radiation Therapy
Current Research and Scholarly InterestsIn addition to my clinical research in head and neck and lung cancer, I work on the application of computer science and machine learning to cancer research. I develop tools for analyzing large datasets to improve outcomes and safety of cancer treatment. I developed a machine learning prognostic model using data from around 13,000 patients with metastatic cancer which performs better than traditional models and physicians [PubMed ID 33313792]. We recently completed a prospective randomized study in thousands of patients in which the model was used to help improve advance care planning conversations.
I also work on the methods underpinning observational and predictive modeling research. My open source nnet-survival software that allows use of neural networks for survival modeling has been used by researchers internationally. In collaboration with the Stanford Research Informatics Center, I examined how electronic medical record (EMR) survival outcome data compares to gold-standard data from a cancer registry [PubMed ID 35802836]. The EMR data captured less than 50% of deaths, a finding that affects many studies being published that use EMR outcomes data. -
Alireza Ghiam, MD, MS
Clinical Associate Professor, Radiation Oncology - Radiation Therapy
BioDr. Ghiam is an American and Canadian Board-Certified Radiation Oncologist with the Stanford Medicine Cancer Center and a Clinical Associate Professor in the Department of Radiation Oncology at Stanford University School of Medicine. After completing an MSc in Molecular Biology & Genetics at the University of Montreal, he completed a residency in Radiation Oncology and fellowship in Head & Neck and GU radiation oncology at the University of Toronto.
He diagnoses and treats various conditions specializing in head & neck cancer, genitourinary malignancies, and metastatic disease. His treatment expertise includes oligometastatic disease, palliative radiation therapy, stereotactic ablative radiotherapy, and proton therapy.
Dr. Ghiam has contributed to the field through his authorship of technology- and biology-based publications and collaboration in clinical trials. He has been recognized by awards from the American Society for Radiation Oncology (ASTRO), the Canadian Association of Radiation Oncology (CARO), and the Universities of Toronto and Pennsylvania. In recognition of his educational work, he received two prestigious teaching awards for teaching residents and medical students. He has presented his research work nationally and internationally and authored and co-authored several papers.
Dr. Ghiam's interest lies in exploring novel AI-powered technologies that can enhance patient outcomes, and bridge health equity gaps in radiation oncology. He is also interested in clinical trials of innovative radiation therapy techniques with a focus on leveraging technology and biology to reduce toxicity and increase precision.
Dr. Ghiam has now joined the prestigious Radiation Oncology Department of Stanford University, where he is dedicated to academia, education, and diversity. He is committed to improving patient outcomes and changing the role of supportive care in radiation oncology by promoting quality standards and utilizing palliative radiotherapy to enhance the quality of life for his patients.
Dr. Ghiam practices evidence-based care with compassion and treats his patients as he would his own family. -
Iris C. Gibbs, MD, FACR, FASTRO
Professor of Radiation Oncology (Radiation Therapy) and, by courtesy, of Neurosurgery
On Partial Leave from 07/05/2023 To 09/29/2023Current Research and Scholarly InterestsDr. Gibbs is a board-certified radiation oncologist who specializes in the treatment of CNS tumors. Her research focuses on developing new radiation techniques to manage brain and spinal tumors in adults and children. Dr. Gibbs has gained worldwide acclaim for her expertise in Cyberknife robotic radiosurgery.
-
Steven Hancock, MD
Professor of Radiation Oncology (Radiation Therapy), Emeritus
Current Research and Scholarly InterestsOutcomes of radiation treatment for prostate cancer. Clinical research interests in the late effects of radiation on normal tissues and chemical modification of radiation injury. Hodgkins's disease and late effects of radiation and combined modality therapy. Radiation sensitizers. Hypoxic cell cytotoxins. Esophageal cancers.
General adult and pediatric radiation therapy. -
Richard Hoppe
Henry S. Kaplan-Harry Lebeson Professor of Cancer Biology
Current Research and Scholarly InterestsIrradiation immunosuppression; total body irradiation;, psychosocial effects of cancer treatment; treatment of lymphoma;, mycosis fungoides.
-
Anusha Kalbasi, M.D.
Associate Professor of Radiation Oncology (Radiation Therapy)
BioDr. Kalbasi is a board-certified radiation oncologist and physician-scientist at the Stanford Cancer Institute. He is also an associate professor of radiation oncology at Stanford Medicine and a project member of the Parker Institute for Cancer Immunotherapy.
Dr. Kalbasi specializes in the diagnosis and treatment of solid tumors, especially sarcoma and melanoma, with a focus on bringing new treatments to patients. This focus includes using advanced techniques in cancer immunotherapy, including CAR T-cell therapy and innate immune agonists.
Dr. Kalbasi's NIH-funded laboratory is actively engaged in translational research with a special focus on developing new immunotherapy treatments for patients with solid tumors, especially sarcoma. A primary focus of his ongoing research involves identifying why some patients do not benefit from treatments like immunotherapy or radiation, then designing and testing strategies to overcome treatment resistance. Dr. Kalbasi is also an experienced leader of clinical trials related to immunotherapy, T cell therapy and radiation therapy, and is a recipient of the Damon Runyon Clinical Investigator Award.
Prior to his arrival at Stanford Health Care, Dr. Kalbasi was assistant professor of radiation oncology in the David Geffen School of Medicine at UCLA and chief of sarcoma radiotherapy at the UCLA Jonsson Comprehensive Cancer Center. During his tenure, he was named a NextGen Star by the American Association of Cancer Research in recognition for excellence in cancer research.
Dr. Kalbasi’s work has been published in leading journals including Nature, Science Translational Medicine, JAMA Oncology, Lancet Oncology, Nature Cancer and Cancer Discovery. He has served as a peer reviewer for multiple prestigious journals, including the Proceedings of the National Academy of Sciences, Cell and the Journal of Clinical Investigation. He has also presented research to his peers at the American Association for Cancer Research and the American Institute of Chemical Engineers. -
Daniel Kapp
Professor of Radiation Oncology, Emeritus
Current Research and Scholarly InterestsGynecologic malignancies; Rectal/and cancer; Breast Cancer; Hodgkin's disease; Hyperthermia; intraoperative radiation therapy; High dose rate radiation therapy; Predictive assays; Patterns of tumor spread; Health care finance.
-
Susan Knox
Associate Professor of Radiation Oncology, Emerita
Current Research and Scholarly InterestsOur interests include 1) study of the effect of radiation on regulatory cell subpopulations and co-stimulatory molecules, 2) use of radiation as an immune modulator for optimization of transplant regimens, 3) the role of radiation in tumor vaccine strategies, 4) study of new radiosensitizers and radioprotectors, and 5) discovery of new targeted therapies for the treatment of solid tumors.
-
Quynh-Thu Le, MD
Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Professor, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS)
Current Research and Scholarly InterestsMy laboratory research interest focuses on the identification of biomarkers for prognosis in patients with head & neck or lung cancers. I am also conducting a number of clinical trials specifically in patients with head & neck cancers.
-
Michael Lim, M.D.
Professor of Neurosurgery and, by courtesy, of Radiation Oncology (Radiation Therapy), of Medicine (Oncology), of Otolaryngology - Head & Neck Surgery (OHNS) and of Neurology
BioDr. Lim is the Chair of the Department of Neurosurgery and a board-certified neurosurgeon specializing in brain tumors and trigeminal neuralgia.
Dr. Lim’s clinical interests include the treatment of benign and malignant brain tumors, with special interest in gliomas, meningiomas, metastatic tumors, and skull base tumors. Dr. Lim also specializes in surgical treatments for trigeminal neuralgia. During his time at Johns Hopkins, Dr. Lim built one of the largest brain tumor and trigeminal neuralgia practices and utilized the most advanced surgical technologies and techniques for his patients. As a passionate voice for patient experience, he has been recognized by his peers and patients for his integrity and compassionate care, including a Service Excellence Award from HealthNetwork Foundation.
As a mentor, he has garnered numerous teaching awards, including being honored as an outstanding teacher by Johns Hopkins University School of Medicine. He is actively involved in shaping education for neurosurgery and oncology across the United States and around the world.
Dr. Lim’s research interests focus on harnessing the immune system to fight cancer. His laboratory focuses on understanding mechanisms of immune evasion by cancer cells. He has successfully translated his findings from the laboratory to the clinics and has conducted and led several large national immunotherapy clinical trials for brain tumors.
Dr. Lim’s bibliography contains well over 200 articles on topics such as immunotherapy for glioblastoma, long-term survival of glioma patients treated with stereotactic radiation, and treatment of neuropathic pain. His work has appeared in Science Translational Medicine, Clinical Cancer Research, Lancet Oncology, Nature Immunology, and many more publications. He also has written 20 book chapters and monographs.
Dr. Lim is a world leader in immunotherapy for brain tumors. In addition to being invited world-wide to give lectures and seminars, he has given platform presentations on the topics of immunotherapy for brain tumors, neurosurgical techniques and management of brain tumors at the American Society of Clinical Oncologists, American Academy of Neurological Surgeons, Radiological Society of North America, Annual Symposium on Brain and Spine Metastases, Congress of Neurological Surgeons, and other meetings. In addition, he has served as platform chairman of the CNS session at the American Society for Clinical Oncology conference.
Dr. Lim is a member of the American Society for Clinical Oncology, Congress of Neurological Surgeons, American Association of Neurological Surgeons, and Society for Neuro-Oncology. Dr. Lim served as the program co-chair of the Society for Neuro-Oncology and CNS section of the American Society for Clinical Oncology. He also served on many executive committees, including the Executive Committee for the Joint Tumor Section of the American Association of Neurological Surgeons and Congress of Neurological Surgeons. -
Billy W Loo, Jr, MD PhD FASTRO FACR
Professor of Radiation Oncology (Radiation Therapy)
Current Research and Scholarly InterestsMy clinical specialty is radiation treatment of thoracic cancers.
My research is on developing next-generation ultra-rapid radiation therapy technology (PHASER) and studying the radiobiological effects of FLASH treatment.
My clinical research is on advanced 4-D image-guided radiation therapy and stereotactic ablative radiotherapy (SABR), and functional and metabolic imaging and imaging biomarkers. -
Carol Marquez, MD
Clinical Professor, Radiation Oncology - Radiation Therapy
BioDr. Marquez is a radiation oncologist and the medical director of the Stanford Cancer Center in South Bay. She has board certification in therapeutic radiology and completed fellowship training in the use of radioimmunotherapy and radiosensitizers.
Dr. Marquez educates future specialists in her position as a clinical professor in the Department of Radiation Oncology at Stanford University School of Medicine.
In her clinical practice, she specializes in breast cancer, but treats a broad spectrum of cancers including prostate, lung, colon, lymphoma, and brain tumors. For each patient, she develops a comprehensive, compassionate care plan customized to individual needs. Her goal is to deliver the most effective cancer treatment to help patients enjoy the best possible health and quality of life.
Dr. Marquez has conducted research and published numerous articles in peer-reviewed journals: Clinical Cancer Research, Annals of Surgical Oncology, the Journal of Women’s Health, and others. Topics include innovations in surgical decision-making, advanced treatment of prostate cancer, and the effectiveness of stereotactic body radiation therapy (SBRT) in treating larger brain tumors.
She also wrote the chapter on pediatric radiation therapy for the Textbook of Clinical Pediatrics.
She has made presentations to her peers at the annual meeting of the American Society for Therapeutic Radiology (ASTRO) and at the annual Radiation Oncology Conference. Topics include radiation therapy after a mastectomy and advanced management of cancer of the central nervous system
She received a grant to examine the recruitment and retention of minority patients in cancer research. The National Cancer Institute sponsored the study.
Dr. Marquez is a member of the American Society for Therapeutic Radiology, American College of Radiology (ACR), and Society for Neurologic Oncology (SNO). She is a Fellow of the American College of Radiology (FACR).
She participates on multiple committees in the Stanford School of Medicine Clinical Educator Program. She also serves as a radiation oncology expert on the Global Online Breast Tumor Board. This board is sponsored by Massachusetts General Hospital and meets monthly to provide real-time expert opinions for breast cancer cases from cancer centers across the world, including Brazil, Poland, and the Philippines. -
Andrew Philip Martella
Clinical Assistant Professor, Radiation Oncology - Radiation Therapy
BioDr. Martella is a fellowship-trained radiation oncologist and a clinical assistant professor of radiation oncology at Stanford University School of Medicine.
His clinical interests include gynecologic, breast, thoracic, gastrointestinal, genitourinary, and central nervous system cancers. His experience encompasses the full range of radiotherapy techniques, including intensity modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), stereotactic body radiotherapy (SBRT), CyberKnife radiosurgery, eye plaque brachytherapy, and prostate and gynecologic high dose rate (HDR) brachytherapy.
Dr. Martella is dedicated to improving the quality of care and the patient experience. He deeply values a close relationship with his patients and their loved ones. He feels that each patient experiences healthcare in a unique and individual way. By recognizing and responding to those individual needs Dr. Martella provides a truly patient-centered experience. He has helped conduct research into noninvasive deep brain stimulation and chromosomal topography,and published on the topic of treating rectal cancer without radiation. He also was the primary contributing author of chapters in the book First Aid for the United States Medical Licensing Examination.
Dr. Martella has delivered presentations at the Annual Meeting of the American Society for Therapeutic Radiology and Oncology. Topics include chemotherapy and radiotherapy in endometrial cancer.
Among the honors for scholarship that Dr. Martella has received, he graduated first in his class at Duke University School of Medicine. He was also elected during medical school into Alpha Omega Alpha Honor Medical Society.
Dr. Martella’s community service has included a position on the board of directors of Camp Good Days and Special Times, a nonprofit organization that provides services for children who have cancer, have a parent or sibling with cancer, or have lost a parent or sibling to the disease. He has served on several leadership roles and has a deep dedication to furthering diversity and inclusion throughout the healthcare system. -
Stavros Melemenidis
Basic Life Research Scientist, Radiation Oncology - Radiation Therapy
Current Role at StanfordI am currently responsible for the design and delivery of the pre-clinical in-vivo irradiations with ultra-high dose-rate (FLASH), using a clinical Linac at the Cancer Center. I deliver irradiation for collaborators but also managing animal experiments for our group; from the development of tumors models and handling of the animals to the design of 3D printed shields for radiation and radiotherapy dosimetry.
-
Lynn Million
Clinical Professor, Radiation Oncology - Radiation Therapy
BioLynn Million specializes in the treatment of cancer. She has practiced Radiation Oncology for more than 30 years. Dr. Million has a special interest in the treatment of sarcoma’s of soft tissue, bone and cartilage in children, young adolescents and adults.
-
Everett J. Moding, MD, PhD
Assistant Professor of Radiation Oncology (Radiation Therapy)
Current Research and Scholarly InterestsMy laboratory performs translational research using analysis of human samples to identify critical mediators of treatment resistance that can be validated in preclinical models and targeted to enhance the efficacy of cancer therapy.
-
Prithvi Mruthyunjaya, MD, MHS
Professor of Ophthalmology and, by courtesy, of Radiation Oncology
Current Research and Scholarly InterestsDr Mruthyunjaya has maintained a broad research interest with publications in both ocular oncology and retinal diseases.
His focus is on multi-modal imaging of ocular tumors and understanding imaging clues that may predict vision loss after ocular radiation therapy. He coordinates multi-center research on the role of genetic testing and outcomes of treatments of ocular melanoma.
In the field of retinal diseases, his interests are in intra-operative imaging to enhance surgical accuracy.
